In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
A new technology captivates investors, igniting a stock market rally, but as prices soar, the inevitable collapse looms. Discover the cyclical nature of market euphoria and its consequences.
